Vanda Pharmaceuticals Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Vanda Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Vanda Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$5.32M, a 3986% decline year-over-year.
  • Vanda Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$16.4M, a 239% decline year-over-year.
  • Vanda Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $2.51M, a 60% decline from 2022.
  • Vanda Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $6.28M, a 81.1% decline from 2021.
  • Vanda Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $33.2M, a 42.1% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$16.4M -$5.32M -$5.46M -3986% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$10.9M -$4.52M -$6.04M -397% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$4.89M -$4.15M -$7.4M -227% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 $2.51M -$2.4M -$9.26M -135% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-08
Q3 2023 $11.8M $137K -$3.13M -95.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $14.9M $1.52M -$1.05M -40.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 $16M $3.25M +$9.68M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 $6.28M $6.86M -$217K -3.07% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-08
Q3 2022 $6.49M $3.27M -$4.5M -57.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $11M $2.57M -$7.08M -73.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 $18.1M -$6.43M -$15.1M -174% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 $33.2M $7.08M -$1.11M -13.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-08
Q3 2021 $34.3M $7.77M +$1.82M +30.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $32.4M $9.65M +$939K +10.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 $31.5M $8.65M +$8.16M +1680% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 $23.3M $8.19M +$3.97M +94.3% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-11
Q3 2020 $19.4M $5.95M -$94.5M -94.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $114M $8.71M -$2.81M -24.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 $117M $486K +$1.1M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 $116M $4.22M -$6.14M -59.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-11
Q3 2019 $122M $100M +$93.3M +1300% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-11
Q2 2019 $28.4M $11.5M +$6.92M +150% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-11
Q1 2019 $21.5M -$612K -$3.68M -120% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-11
Q4 2018 $25.2M $10.4M +$12.2M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 $13M $7.17M +$11.7M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 $1.29M $4.61M +$6.15M Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 -$4.86M $3.07M +$10.7M Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 -$15.6M -$1.84M -$1.23M -204% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-19
Q3 2017 -$14.3M -$4.55M -$4.12M -958% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-19
Q2 2017 -$10.2M -$1.53M +$3.08M +66.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-19
Q1 2017 -$13.3M -$7.65M +$4.71M +38.1% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-19
Q4 2016 -$18M -$604K +$14.2M +95.9% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-15
Q3 2016 -$32.2M -$430K +$9.03M +95.5% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-15
Q2 2016 -$41.2M -$4.62M +$768K +14.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-15
Q1 2016 -$42M -$12.4M -$2.14M -20.9% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-15
Q4 2015 -$39.9M -$14.8M -$84.5M -121% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-17
Q3 2015 $44.7M -$9.46M -$8.04M -563% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-17
Q2 2015 $52.7M -$5.39M +$16.2M +75% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-17
Q1 2015 $36.5M -$10.2M +$16.3M +61.5% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-17
Q4 2014 $20.2M $69.7M +$77.5M Oct 1, 2014 Dec 31, 2014 10-K 2016-02-12
Q3 2014 -$57.3M -$1.43M +$3.98M +73.6% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-12
Q2 2014 -$61.3M -$21.6M -$18.2M -538% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-12
Q1 2014 -$43.1M -$26.5M -$22M -487% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-12
Q4 2013 -$21.1M -$7.75M -$1.38M -21.6% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-13
Q3 2013 -$19.7M -$5.41M -$80K -1.5% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-13
Q2 2013 -$19.6M -$3.38M +$4.62M +57.7% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-13
Q1 2013 -$24.2M -$4.52M +$3.44M +43.2% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-13
Q4 2012 -$27.7M -$6.37M -$846K -15.3% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-25
Q3 2012 -$26.8M -$5.33M -$2.25M -73.3% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-25
Q2 2012 -$24.6M -$8.01M -$6.67M -497% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-25
Q1 2012 -$17.9M -$7.96M -$8.1M -5954% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-25
Q4 2011 -$9.8M -$5.52M Oct 1, 2011 Dec 31, 2011 10-K 2013-02-26
Q3 2011 -$3.07M -$6.26M -197% Jul 1, 2011 Sep 30, 2011 10-K 2013-02-26
Q2 2011 -$1.34M -$2.62M -205% Apr 1, 2011 Jun 30, 2011 10-K 2013-02-26
Q1 2011 $136K Jan 1, 2011 Mar 31, 2011 10-K 2013-02-26
Q3 2010 $3.18M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-07
Q2 2010 $1.28M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.